Amgen Inc. (NASDAQ:AMGN) Stock Position Lessened by Capital Research Global Investors

Capital Research Global Investors lowered its position in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 16.8% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 18,431,551 shares of the medical research company’s stock after selling 3,726,355 shares during the period. Amgen accounts for 1.1% of Capital Research Global Investors’ investment portfolio, making the stock its 20th largest position. Capital Research Global Investors’ holdings in Amgen were worth $4,457,122,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also bought and sold shares of the company. AIA Group Ltd boosted its position in shares of Amgen by 40.4% in the 1st quarter. AIA Group Ltd now owns 2,938 shares of the medical research company’s stock valued at $710,000 after purchasing an additional 845 shares during the period. Dixon Hughes Goodman Wealth Advisors LLC boosted its position in shares of Amgen by 905.2% in the 1st quarter. Dixon Hughes Goodman Wealth Advisors LLC now owns 1,156 shares of the medical research company’s stock valued at $280,000 after purchasing an additional 1,041 shares during the period. IndexIQ Advisors LLC boosted its position in shares of Amgen by 2.3% in the 1st quarter. IndexIQ Advisors LLC now owns 10,095 shares of the medical research company’s stock valued at $2,441,000 after purchasing an additional 225 shares during the period. Lindbrook Capital LLC boosted its position in shares of Amgen by 16.7% in the 1st quarter. Lindbrook Capital LLC now owns 2,358 shares of the medical research company’s stock valued at $570,000 after purchasing an additional 337 shares during the period. Finally, Sante Capital Fund LP acquired a new position in shares of Amgen in the 1st quarter valued at $3,118,000. Institutional investors own 77.14% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $226.86 on Wednesday. The company has a debt-to-equity ratio of 14.76, a current ratio of 1.53 and a quick ratio of 1.17. The company has a market capitalization of $121.35 billion, a PE ratio of 19.23, a price-to-earnings-growth ratio of 2.00 and a beta of 0.56. Amgen Inc. has a one year low of $198.64 and a one year high of $258.45. The business has a 50 day simple moving average of $246.02 and a 200 day simple moving average of $243.53.

Amgen (NASDAQ:AMGNGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The medical research company reported $4.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.25. Amgen had a return on equity of 218.34% and a net margin of 24.92%. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.53 billion. During the same quarter in the previous year, the company posted $4.38 EPS. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen Inc. will post 17.45 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Thursday, August 18th were given a $1.94 dividend. The ex-dividend date of this dividend was Wednesday, August 17th. This represents a $7.76 annualized dividend and a yield of 3.42%. Amgen’s payout ratio is 65.76%.

Analyst Ratings Changes

AMGN has been the subject of several research analyst reports. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 8th. Robert W. Baird reissued an “underperform” rating and issued a $185.00 price objective on shares of Amgen in a research note on Tuesday. Morgan Stanley raised their price objective on Amgen from $239.00 to $253.00 and gave the company an “equal weight” rating in a research note on Friday, July 15th. Atlantic Securities cut their price objective on Amgen from $190.00 to $182.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 9th. Finally, SVB Leerink began coverage on Amgen in a research note on Monday, May 23rd. They issued a “market perform” rating and a $256.00 price objective on the stock. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $241.13.

Insider Buying and Selling at Amgen

In related news, Director R Sanders Williams sold 200 shares of Amgen stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $249.96, for a total transaction of $49,992.00. Following the completion of the sale, the director now directly owns 5,301 shares of the company’s stock, valued at $1,325,037.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Amgen news, Director Robert Eckert sold 6,600 shares of the business’s stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $249.00, for a total value of $1,643,400.00. Following the completion of the transaction, the director now directly owns 21,184 shares of the company’s stock, valued at $5,274,816. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director R Sanders Williams sold 200 shares of the business’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $249.96, for a total value of $49,992.00. Following the completion of the transaction, the director now directly owns 5,301 shares of the company’s stock, valued at $1,325,037.96. The disclosure for this sale can be found here. Corporate insiders own 0.46% of the company’s stock.

About Amgen

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.